GOTO-GROUP
11.4.2022 05:41:13 CEST | Business Wire | Press release
PT GoTo Gojek Tokopedia Tbk (“GoTo Group'' or the “Company”), the largest digital ecosystem in Indonesia, today announced its listing on the Main Board of the Indonesia Stock Exchange (IDX), where its shares will trade under the stock code GOTO. The total amount raised from the Group’s Initial Public Offering (IPO) process is approximately USD1.1 billion (IDR15.8 trillion), comprising USD954.7 million (IDR13.7 trillion) in proceeds plus USD146.3 million (IDR2.1 trillion) from treasury shares for the purpose of over allotment, representing a market capitalisation of approximately USD28 billion (IDR400.3 trillion).
Based on the total funds raised, GoTo’s IPO is the third largest in Asia and fifth largest in the world this year.1 Around 300,000 investors have participated - the highest ever number to take part in an IPO on the IDX.
As part of the drive to make this IPO one of the most inclusive, GoTo has introduced the Gotong Royong Share Program. The company has allocated over US$20 million2 to driver-partners, as well as forming the GoTo Future Fund - an endowment fund that aims to support initiatives and solutions that benefit the lives of stakeholders across the GoTo ecosystem. Loyal merchants and consumers in Indonesia were able to benefit from the IPO, receiving priority access to order a fixed allocation of GoTo shares. Furthermore, as part of the program, all full time employees have been made participants in the Group's Long-Term Incentive Plan.
Andre Soelistyo, GoTo Group CEO said , “Today we embark on a new journey as a public company. Our listing on the Indonesia Stock Exchange will strengthen our ability to pursue our mission and better serve customers. Despite global market volatility, investor interest has been strong, reflecting the rapidly growing demand in Southeast Asia for our on-demand, e-commerce and financial technology services, as well as confidence in GoTo's position as the largest digital ecosystem in Indonesia.
“Ultimately, the people who deserve the most recognition for today's milestone are the people who worked so hard to breathe life into our business. Our success can be wholly attributed to our driver-partners, merchants, consumers and employees, and it was therefore a priority for us to ensure they could benefit from our IPO via the Gotong Royong Share Program, one of the most inclusive share ownership programs in the world today. With all of these groups working together, we are truly unstoppable as we pursue our mission to empower progress for Indonesia and Southeast Asia.
“I would also like to express our gratitude to the Government of Indonesia, the OJK, and IDX for their support during the IPO process, and for their continued commitment to the growth of Indonesia’s digital economy. Together we can help to support Indonesia’s digital transformation by leveraging technology for the benefit of all.”
The listing ceremony and the handover of the listing certificate took place today at the Indonesia Stock Exchange, in Jakarta, and was attended by Coordinating Minister for Economic Affairs Airlangga Hartarto, Chairman of the Board of Commissioners of OJK Wimboh Santoso, and IDX’s President Director Inarno Djajadi.
GoTo Group’s listing represents a historic moment for the Company and the IDX, as the first listing to be carried out under the new regulations on multiple voting rights set out by the OJK. The Company offered a total of 46.7 billion Series A shares, comprising newly issued, and treasury shares (for the purpose of over allotment) at an offer price of IDR338, representing a projected market capitalization of approximately USD28 billion (IDR400.3 trillion) at admission.
A long-term strategy for growth
GoTo Group plans to use the proceeds from the IPO, after deducting issuance costs, for working capital to support the Company’s growth strategy, comprising four pillars:
- Driving customer growth and engagement through cross pollination and by increasing usage among consumers, merchants and driver-partners.
- Enhancing hyperlocal experiences and infrastructure to provide consumers with more convenience in their digital daily lives.
- Strengthening ecosystem synergies including enhanced loyalty and rewards programs, deeper financial services offerings and further development of value added merchant services.
- Investing in high growth areas , including deeper demographic expansion in Indonesia, Singapore and Vietnam, targeted strategic investments, investment in technology and infrastructure, and the transition towards electric vehicles.
GoTo Group is the market leader in Indonesia in each of its business verticals and by strengthening the synergies and network effects from within its ecosystem, the Group is well positioned for continued growth. GoTo Group has already achieved:
- Pro forma3 Gross Transaction Value (GTV) of IDR414.2 trillion (USD28.8 billion) in the 12-months ended 30 September 2021
- Pro forma Gross Revenue of IDR15.1 trillion (USD1 billion) in the 12-months ended 30 September 2021
- Pro forma Orders of approximately 2 billion in the 12-months ended 30 September 2021
- Over 55 million annual transacting users (ATU) on a pro forma basis, as of 30 September, 2021
- Over 2.5 million registered driver partners, as of 30 September, 2021
- Over 14 million registered merchants, as of 30 September, 2021
Indonesia represents Southeast Asia’s largest economy, contributing a GDP of more than USD1 trillion and a population of 274 million - the fourth largest in the world. Indonesia and Southeast Asia have a young and highly tech-savvy population with increasing spending power that is driving the growth of the region’s digital economy.
Growing demand for services across GoTo Group’s ecosystem, driven by increasing digital adoption among consumers in Southeast Asia, has underpinned the Group’s strong financial performance in recent years. GoTo Group’s pro forma GTV grew at 46% CAGR between 2018 and 2020, and at 62% YoY between Q3 2020 and Q3 2021. Pro forma gross revenue grew at 56% CAGR between FY2018 and FY2020 and 55% YoY between Q3 2020 and Q3 2021.
PT Indo Premier Sekuritas, PT Mandiri Sekuritas, and PT Trimegah Sekuritas Indonesia Tbk acted as the Joint Lead Underwriters for the IPO.
Notes to editors:
https://www.gotocompany.com/investor-relations/prospectus
For more information on GoTo and the IPO, please see the Prospectus at gotocompany.com.
Definition of pro-forma : The pro forma information of GTV, Orders, ATU and gross revenue provided is as if Tokopedia had been consolidated by GoTo since January 1, 2018.
Exchange rate: IDR14.350 = USD1
About GoTo Group:
PT GoTo Gojek Tokopedia Tbk (GoTo Group) is the largest digital ecosystem in Indonesia. GoTo's mission is to "empower progress" by offering technology infrastructure and solutions that help everyone to access and thrive in the digital economy. The GoTo ecosystem consists of on-demand services (mobility, food delivery, and logistics), e-commerce (third party marketplaces + official stores, instant commerce, interactive commerce, and rural commerce), and financial technology (payments, financial services, and technology solutions for merchants) through the Gojek, Tokopedia, and GoTo Financial platforms.
___________________________
1
Source: Bloomberg
2
Value based on opening share price of IDR 338 per share
3
See notes to editors for pro forma definition.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220410005062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
